Nexien Biopharma, Inc. Reports Earnings Results for the Third Quarter Ended March 31, 2020
May 14, 2020 at 01:42 pm
Share
Nexien BioPharma, Inc. announced earnings results for the third quarter ended March 31, 2020. For the third quarter, the company announced net loss was USD 559,670 compared to USD 484,810 a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago. For the nine months, net loss was USD 1.997 million compared to USD 3.241 million a year ago. Basic loss per share from continuing operations was USD 0.04 compared to USD 0.06 a year ago.
Nexien BioPharma, Inc. is engaged in pre-clinical and drug development activities for certain pharmaceutical formulations that include cannabinoids. The Company is focused on developing and commercializing United States Food and Drug Administration (FDA)-compliant cannabinoid pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders and medical conditions. Its flagship research and development programs are focused on advancing formulations that have the potential to improve the treatment outcomes of certain convulsive disorders and neuromuscular disorders, which includes the treatment of myotonic dystrophy. The Company's wholly owned subsidiaries include Intiva BioPharma Inc., NexN Inc. (NexN) and NexDM Inc.
NEXIEN BIOPHARMA, INC. 
